Search results for Olokizumab
Olokizumab Biosimilar – Anti-IL6 mAb – Research Grade, ProteoGenix, PX-TA1247
Description of Olokizumab Biosimilar - Anti-IL6 mAb - Research Grade General information on Anti-IL6[Homo sapiens] (Olokizumab) Monoclonal Antibody Olokizumab has been investigated for the treatment of Crohn’s Disease.
Host
Reactivity
Applications
Conjugation
Olokizumab, Abbexa, abx831202
Olokizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL6, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Olokizumab has been used in trials studying the treatment of Crohn's Disease.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Olokizumab ELISA Kit, ProteoGenix, KPTX150
Description of Olokizumab ELISA Kit Introduction Olokizumab is a humanized monoclonal antibody that specifically targets the interleukin-6 (IL-6) cytokine. It has been developed as a potential therapeutic agent for inflammatory diseases, particularly rheumatoid arthritis (RA). In order to study the levels of olokizumab in biological samples, an enzyme-linked immunosorbent assay (ELISA) kit has been developed. In this article, we will discuss the structure, activity and application of the Olokizumab ELISA Kit. Structure of Olokizumab Olokizumab is a recombinant humanized IgG4 monoclonal antibody that is composed of two heavy chains and two light chains. The heavy chains consist of a constant region and a variable region, while the light chains have only a variable region. The variable regions are responsible for binding to the IL-6 cytokine. Olokizumab has a molecular weight of approximately 148 kDa and a half-life of 21 days. Activity of Olokizumab Olokizumab binds to the IL-6 cytokine with high affinity and specificity, preventing its interaction with the IL-6 receptor and subsequent downstream signaling. This inhibits the pro-inflammatory effects of IL-6, such as the activation of immune cells and the production of other inflammatory cytokines. Olokizumab has been shown to effectively reduce the symptoms and progression of RA in clinical trials. Application of Olokizumab ELISA Kit The Olokizumab ELISA Kit is a quantitative assay that is used to measure the levels of olokizumab in biological samples, such as serum, plasma, and synovial fluid. This kit utilizes a sandwich ELISA method, where the olokizumab in the sample is captured by an immobilized anti-human IgG antibody and then detected by a biotinylated anti-human IL-6 antibody. The amount of olokizumab present in the sample is directly proportional to the color intensity, which can be measured spectrophotometrically. Advantages of Olokizumab ELISA Kit The Olokizumab ELISA Kit has several advantages over other methods of olokizumab detection. Firstly, it is a highly sensitive and specific assay, with a detection limit of 0.1 ng/mL. This allows for accurate measurement of low levels of olokizumab in biological samples. Secondly, the kit is easy to use and can be performed in a relatively short amount of time. This makes it a convenient tool for researchers and clinicians. Lastly, the Olokizumab ELISA Kit has been validated for use with multiple sample types, making it a versatile assay for different research purposes. Clinical Applications The Olokizumab ELISA Kit has been used in various clinical studies to measure the levels of olokizumab in patients with RA. It has been shown to effectively monitor the pharmacokinetics of olokizumab, as well as assess its efficacy in reducing RA symptoms. In addition, the kit has also been used in preclinical studies to evaluate the pharmacokinetics and pharmacodynamics of olokizumab in animal models. Conclusion The Olokizumab ELISA Kit is a valuable tool for studying the levels of olokizumab in biological samples. Its high sensitivity, specificity, and ease of use make it a preferred method for researchers and clinicians. With the promising results of olokizumab in clinical trials, the Olokizumab ELISA Kit will continue to play an important role in the development and evaluation of this potential therapeutic agent for inflammatory diseases.
Host
Reactivity
Applications
Conjugation
Olokizumab ELISA Kit, Abbexa, abx395039
Olokizumab ELISA Kit is a quantitative ELISA kit for detection of Olokizumab.Olokizumab (CDP6038), a humanized monoclonal antibody (mAb) specific for the interleukin-6 (IL-6) cytokine, is currently in development for the treatment of rheumatoid arthritis (RA). It targets the IL-6 cytokine rather than the receptor, and selectively blocks the final assembly of the signalling complex. In Phase I (healthy volunteers) and IIa (patients with RA on MTX) clinical trials, olokizumab was well tolerated after intravenous and subcutaneous delivery with a median plasma half-life of approximately 31 days, 76% bioavailability and no apparent antidrug antibody-mediated clearance. Olokizumab also markedly reduced free IL-6 levels and suppressed C-reactive protein (CRP) up to 12 weeks after single-dose subcutaneous administration in patients with RA.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Olokizumab Biosimilar - Research Grade, ichor.bio, ICH5170
Detects human IL-6
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.